- Extensive in-house experience in industrial drug discovery and development for small-molecule pharmaceuticals.
- Strong patent application preparation and prosecution experience in technological disciplines ranging from organic chemistry, polymers, advanced materials, cosmetics, drug discovery and development, and biological sciences, to semiconductor and LED manufacturing.
- Freedom-to-operate and validity studies in support for strategic legal counseling, negotiations, business transactions, planning, licensing and venture capital investments.
- Strong skills in legal and technical due diligence.
Prior to joining Abel IP, Thomas was a patent practitioner for six years with Greenblum & Bernstein PLLC, in the DC metro area. There, he developed a close working relationship with the USPTO, interviewing Examiners regularly, and practicing with and mentoring under senior attorneys, many of whom were ex-Examiners from the USPTO. Previous to that, Thomas was a scientist in the drug discovery and development department at AstraZeneca R&D in Waltham, Massachusetts.
Area of Practice
- Intellectual Property
- Technology Transactions
- New Materials
- Small-Molecule Pharmaceuticals
- Synthetic Biology
- Medical Devices
- Semiconductor Manufacturing
- Licensed to practice before the U.S. Patent and Trademark Office
- American Chemical Society
- German Chemical Society (GDCh)
- Ph.D. (Organic and Medicinal Chemistry), University of Houston, TX, 2002
- J.D., The Catholic University of America, Columbus School of Law, Washington, D.C. 2010
- Dipl. Chem., Universität des Saarlandes, Germany, 1997
- Co-inventor of “Oxazolidinone and/or Isooxazoline derivatives as Antibacterial Agents” International Patent Appl. Pub. # WO 2004/048392 A1
- Co-inventor of “Novel Rho Inhibitors” International Patent Appl. Pub. # WO 2004/004464 A1
- First Author of “Metals in Rho-mediated processes: New leads for drug discovery”, Biochemistry 42, (2002), 9121-9126
- First Author of “Metal Dependency for Transcription Factor Rho Activation” Biochemistry 42, (2002), 1652-1659
- First Author of “The Mg2+ Requirements for Rho Transcription Termination Factor: Catalysis and Bicyclomycin Inhibition” Biochemistry 41, (2002), 12377-12383